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Abstract
A library of oligomeric compounds was synthesized based on the imidazole-4,5-dicarboxylic acid
scaffold along with amino acid esters and chiral diamines derived from amino acids. The final
compounds incorporate non-polar amino acids (Leu, Phe, Trp), polar amino acids (Ser, Asp, Arg),
and neutral amino acids (Gly, Ala), and where designed to be useful in screening for inhibitors of
protein-protein interactions. Many of the protected and deprotected oligomers show evidence of
conformational isomers persistent at room temperature in aqueous solution. A total of 317 final
oligomers, out of 441 targeted compounds, were obtained in high analytical purity and of sufficient
quantity in order to submit them for high-throughput screening as part of the NIH Roadmap.
Introduction
The design and preparation of compound libraries for application in high-throughput screening
is a well-known approach to hit identification in drug discovery research.1,2 The library design
criteria are generally target dependent, with the choice of scaffold or building blocks
determined by considering known bioactive compounds or hypothesis or both.3-5
Protein-protein interactions (PPI) are significant events in signaling within and between cells,
and as such are potential targets for intervention by small molecules in order to modulate or
treat diseases related to these signals.6-10 The design of inhibitors for PPIs has, in the past,
been considered intractable due to the size and flatness of the associating surfaces. Yet, most
buried interfaces rely on “hot spots” that require relatively few residues in order to obtain the
majority of the thermodynamic driving force for the PPI.11,12 Thus, targeting a PPI “hot spot”
is a practical approach to reduce the overall size and molecular weight of a potential PPI
inhibitor.
Good progress toward the design and discovery of inhibitors of PPIs has been reported in recent
years by generating a suitable mimic of one of the two protein surfaces.13-18 In general these
inhibitors mimic secondary structures, such as β-turns,3,10 β-strands,19 or an α-helix,9,10,20 in
order to accurately display important residues or “hot spots” of the PPI in a proper orientation.
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This approach can yield compounds with drug-like or nearly drug-like features;21,22 therefore,
the use of inhibitors of PPIs as therapeutic agents is anticipated.23
We have previously employed the imidazole-4,5-dicarboxylic acid scaffold in the design of
CD81 proteomimetics that were based on the comparable distance between carbon atoms of
the imidazole-4,5-dicarboxamide (I45DC) substituents with the spacing of side chains in a
critical α-helix within the PPI.24,25 These first-generation oligomeric I45DCs were symmetric
and utilized two L-amino acids as well as a N,N′-dialkylalkanamine in their design and
synthesis.26 Selected oligomers were effective as inhibitors of the CD81-hepatitis C
glycoprotein E2 interaction, thereby supporting our design hypothesis.24
The second-generation oligomeric I45DCs in this project likewise anticipate the distance
between substituents on each I45DC to match the distance between side chains found along
the length of an α-helix or adjacent along one side of a β-strand.25 The total of four amino acid
side chains per oligomer in this design is expected to be a significant improvement and doubles
the number of pharmacophoric side chains as compared with the first-generation oligomers.
Although only a few amino acids are often involved in a PPI hot spot,11,12 we nonetheless
reason the oligomers in this project have greatly improved odds of yielding inhibitors of PPIs
when employed in high-throughput screening.
The number and type of amino acid building blocks that we employed for these oligomeric
I45DCs was based on a compromise between those amino acids expected to be important in
PPI hot spots and the number of compounds we could reasonably synthesize, purify, and
characterize in parallel. Also guiding our selection was the knowledge that aromatic, polar,
and ionic amino acid side chains were of equal or greater significance to hydrophobic
interactions in many PPIs, such as those in antibody-antigen or enzyme-protein inhibitor
interactions.27,28 The oligomeric design uses combinations of two ethylenediamines along
with two L-amino acids. Two of the three ethylenediamines used are chiral with Ala and Leu
side chains, and were synthesized from their L-amino acids. The seven L-amino acids we chose
included two aromatic residues (Tp and Phe), two hydrophobic residues (Leu and Ala), two
charged residues (Asp and Arg) and one polar residue (Ser). The monomeric I45DCs were also
differentially protected in order to allow selective deprotection of the amino and carboxylic
acid termini before coupling in parallel to create a maximum of 441 unique oligomeric I45DCs.
A total of 317 of these pure oligomeric I45DCs have been characterized and were obtained in
sufficient quantity for submission to the Molecular Library Small Molecule Repository
(MLSMR) for use in high-throughput screening as part of the NIH Roadmap.
Results and Discussion
Ethylenediamine was mono-protected to yield 12{1}, as shown in Scheme 1, by following a
literature procedure.29 This compound was further protected with a known procedure30 to give
11{1} and then selectively deprotected to give 6{1} as the free amine, thereby providing the
two differentially monoprotected ethylenediamines, 6{1} and 12{1} needed for oligomer
synthesis. The other chiral diamines used in this project were synthesized from L-amino acids
bearing either N-Boc or N-Cbz protecting groups as shown in Table 1. Boc-L-amino acids, 1
{2-3}, were the starting materials for the chiral diamines 6{2-3} as shown in Scheme 2. The
amino acids 1{2-3} were converted to their respective methyl esters, 2{2-3}, by slight
modification of a known procedure,31 converted to amides 3{2-3} with an NH4OH solution,
32 and subsequently reduced to the chiral diamines 4{2-3} with BH3·S(CH3)2 in THF.33 These
intermediates were not purified, but first protected with Cbz-Cl to give 5{2-3} following
purification.30 Deprotection of the Boc group in 5{2-3} with CF3CO2H in CH2Cl2 yielded 6
{2-3}. Likewise, Cbz-L-amino acids, 7{2-3}, were starting materials for the chiral diamines
12{2-3} as shown in Scheme 3. The synthesis again proceeded through methyl esters 8{2-3},
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amides 9{2-3}, reduced intermediates 10{2-3}, and the differentially-protected chiral diamines
11{2-3}. Hydrogenation then produced the final chiral diamines 12{2-3} needed for oligomer
synthesis.
The oligomeric design uses the two chiral, mono-protected diamine chemsets 6 and 12 that
were synthesized from amino acid amides, along with the two L-amino acid chemsets 14 and
18. The two halves of the oligomers come from chemsets 16 and 20 that are independently
synthesized with orthogonal protecting groups in order to allow selective deprotection of these
monomeric building blocks (Scheme 4).
Synthesis of the monomeric building blocks begins with the pyrazine diacid chloride, 13, which
is prepared from imidazole-4,5-dicarboxylic acid as previously reported.34 The amino acid
ester-substituted pyrazine chemsets 15 and 19 were likewise prepared by following methods
previously reported, generally giving good to excellent yields of product (Table 3).26,35
The monomeric building blocks with a Cbz-protected amino group, chemset 16, were prepared
by reacting pyrazine chemset 15 with the Cbz-protected diamine chemset 6 in CH2Cl2 at room
temperature from 5-120 hours. These products were purified by column chromatography with
EtOAc/hexanes as the eluant. Product was not obtained for 16{2,7} and 16{3,7}. The reason
for reagent failure as well as identification of the reaction product(s) for these two reactions
was not done. These reactions were attempted more than once with the same results. Reaction
yields for the remaining chemset compounds of 16 ranged from 30-80% and averaged 58%.
Likewise, monomeric building blocks with a benzyl ester-protecting group, chemset 20, were
prepared by reacting pyrazine chemset 19 with the N-Boc protected diamine chemset 12 in
CH2Cl2 at room temperature from 1-72 hours. These products were likewise purified by
column chromatography with EtOAc/hexanes as the eluant. Product was not obtained for 20
{3,5} and the reason for this was not further investigated. Reaction yields for the remaining
chemset compounds of 20 ranged from 25-89% and averaged 66%.
The Cbz and benzyl ester, respectively, for isolated chemset intermediates 16 and 20 were
deprotected with 1 atm. H2 and 5% Pd/C in MeOH. The reactions were stirred at room
temperature from 4.5-29 h for chemset 16 and 11-30 h for chemset 20, at which point the
reaction was complete as determined by TLC analysis. The reaction mixture was filtered
through celite and the solvent removed under vacuum to afford chemsets 17 and 21,
respectively, from chemsets 16 and 20, minus members 17{2,7}, 17{3,7}, and 21{3,5} for
which starting materials were unavailable. The yields for chemset 17 ranged from 84-99% and
averaged 94%, whereas the yields for chemset 21 ranged from 65-100% and averaged 89%.
All of the products were suitable for use without further purification.
The protected oligomer chemset 22, excluding those examples where monomeric intermediates
17{2,7}, 17{3,7}, and 21{3,5} were unavailable, were prepared in CH2Cl2 at room temperature
over 20 h by coupling chemsets 17 and 21 with the water-soluble carbodiimide, EDC·HCl, and
dimethylaminopyridine.36 The reaction mixtures were concentrated under vacuum and the
product purified by column chromatography with a gradient ranging from EtOAc/hexanes to
EtOAc/MeOH as the eluents, affording chemset 22.
Out of the 361 possible combinations for which monomeric chemset intermediates 17 and
21 were available, a total of 323 products were purified and yields determined, which were
generally good (Table 4). The compounds of the protected oligomer chemset 22 were
characterized by combined LC-MS and 1H NMR spectroscopy (see supporting information).
In a few cases a library member was identified by LC-MS, but was not completely characterized
or carried forward due to insufficient amounts of material or contamination with impurities.
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Quantitative deprotection of products of chemset 22 was done with 25% CF3CO2H in
CH2Cl2 at room temperature over 2-18 h, using LC-MS analysis to determine when the reaction
was complete.
Following removal of the solvents, the trifluoroacetate salt was exchanged for chloride by
dissolving the deprotected oligomer chemset 23 in 0.90 mL of 10% aqueous MeOH with gentle
heat as needed for solubilization and adding 100 μL of 1 M HCl. The solutions were
immediately frozen in liquid N2 before lyophilizing to dryness.
Interestingly, we observed two significant signals in the LC-MS analysis of 45 of the protected
oligomer library compounds. In all cases both signals have an identical MS spectra that is
consistent with the proposed structure. We hypothesize that this is evidence of two conformers
that are stable under the conditions of the analysis. Indeed, conformational isomers have been
reported for comparable oligomers containing two N-methylimidazole-4,5-dicarboxylic acid
rings.37 A majority of the hypothesized conformational isomers that are observed have
hydrophobic amino acid side chains located in both substituent amides of chemset, such as
combinations of leucine or phenylalanine (see supporting information). However, we do not
observe such conformational isomers in the protected oligomers containing tryptophan in
chemset 21. It is possible that this is due to a preference for one conformer with the larger
tryptophan substituent as compared with leucine or phenylalanine, or that these conformational
isomers simply do not resolve in the LC-MS for those examples.
Our hypothesis of conformational isomers in protected oligomer chemset 22 is further
supported by the fact that many compounds show broad and poorly defined 1H NMR spectra,
whereas others have comparably well defined signals. Figure 1 compares part of the LC-MS
and 1H NMR spectra for 22{2,1,2,2} with 22{2,1,3,2}. Oligomer 22{2,1,2,2} showed only a
single peak in the LC-MS analysis while 22{2,1,3,2} shows two peaks hypothesized to be the
conformational isomers. The 1H NMR spectra in the aliphatic region for 22{2,1,2,2} is
considerably more defined than the comparable region for 22{2,1,3,2}. The broadness of
the 1H NMR spectra for 22{2,1,3,2} is therefore hypothesized to result from the presence of
conformational isomers having overlap in their 1H NMR chemical shifts or the relative
dynamics of the compound on the NMR time scale or both. It is noted, however, that a
broad 1H NMR spectrum did not necessarily mean that the oligomer showed two peaks in the
LC-MS analysis, since there are examples of this behavior also. Among the potential
explanations for this differing behavior include overlap in the retention time of persistent
conformers in the LC conditions or that the change in solvent from aqueous CH3CN (LC-MS)
versus CDCl3 (1H NMR) alters the conformational behavior between the analyses.
One concern was that the two signals in the LC-MS analysis represent diasteromeric oligomers
resulting from epimerization of a stereocenter under the coupling conditions. We did not expect
the coupling conditions to cause in significant epimerization, and note that we observe two
signals only in select cases for any given set of hydrophobic amino acids. This variability in
behavior is strong evidence against epimerization as the explanation for our results.
As with the protected oligomers, two significant LC-MS signals were observed in 54 of final
compounds of chemset 23. Again, the general trend appears to be related to the presence of
two hydrophobic amino acids in chemset 21, although there are exceptions in the deprotected
oligomers just as there were for the protected oligomers. Importantly, some protected oligomers
with two conformers did not show two conformers when deprotected (e.g., 23{2,2,3,2} and 23
{2,2,3,3}), while others did not show two conformers until the oligomer was deprotected
(e.g., 23{1,2,3,4} and 23{1,3,3,4}). This is yet further evidence against the formation of
diasteromers in the coupling reactions, as diastereomeric compounds of chemset 22 would
yield diastereomeric compounds of chemset 23.
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As additional evidence in support of the conformational hypothesis, we performed variable-
temperature LC-MS on four deprotected oligomers (23{1,2,3,3}, 23{1,3,3,4}, 23{2,5,3,3},
and 23{1,6,3,3}) that show evidence of two peaks in the LC-MS analysis (see supporting
information). The analysis was run from 25 °C to 65 °C, and showed a steady decline in the
relative amounts of the lesser conformer as compared to the major conformer. While we did
not observe coalescence of the two conformers at 65 °C, it is possible that hydrophobic
interactions could continually stabilize the conformation(s) in an aqueous environment.
Nonetheless, the differing relative amounts of the two peaks support our hypothesis that these
are conformational isomers rather than diastereomers.
It is commonplace to use VT-NMR spectroscopy in order to examine conformational
isomerism in solution. We know from our previous experience with monomeric derivatives
that self-association occurs at or above 1 mM in CDCl3 and above 10 mM in DMSO-d6.39
Thus, VT-NMR was performed from 30 °C to 70 °C in DMSO-d6 for 22{2,1,2,2} and 22
{2,1,3,2} at 3 mM (see supporting information), resulting in similar 1H NMR spectra observed
for both compounds across the range of temperatures. We are unable to assign specific NHs
to observed signals, but can nonetheless identify the two imidazole NHs as those signals around
13 ppm, the two amide NHs involved in intramolecular hydrogen bonding as the signals around
11 ppm, the three remaining amide NHs between 8-9 ppm, and the carbamate NH near 7 ppm,
as shown in Figure 2 for 22{2,1,3,2}. From inspection it is then clear that there are
conformational isomers present in the solution. For example, there are four signals for the two
intramolecular hydrogen bonded hydrogens (b). An increase in temperature yields only modest
changes on the chemical shifts of the NHs over this entire region. This has previously been
reported for oligomeric I45DCs that form conformation isomers observable in DMSO-d6 even
at 100 °C.37 Cooling the NMR sample of 22{2,1,3,2} to 30 °C from 70 °C yields the same
spectrum as first recorded at 30 °C, indicating the stability of the compounds in a polar solvent
at high temperatures.
We suggest that the conformational isomers may result from differing intramolecular hydrogen
bonding interactions, particularly around the I45DC from chemset 21, and perhaps supported
by the presence of hydrophobic interactions that protect the hydrogen bond from fast exchange
during the LC-MS analysis and on the 1H NMR time scale. We have previously observed two
intramolecularly hydrogen bonded conformations in dissymmetrically-disubstituted I45DCs
and provided evidence that the favored hydrogen bond donor arose from increasing substitution
adjacent the amide nitrogen.38 Moreover, we have shown in model I45DCs that the
intramolecular hydrogen bond is relatively strong and worth least 14±1 kcal/mol, as well as
observed in an aqueous environment.39 The two conformations for 22{2,1,3,2} shown in
Figure 2 are therefore real possibilities for explaining the observed behavior in both the LC-
MS analysis and 1H NMR spectra. It is reasonable that 22{2,1,2,2} would also adopt analogous
intramolecularly hydrogen bonded conformations, and the lack of a second hydrophobic side
chain may increase the dynamics of the conformational exchange.
The expected intramolecular hydrogen bonding conformations were a valuable design criteria
as they fix the distance between amide substituents in order to approximate the separation of
nearby side chains in α-helices and β-strands.24,25 The two different conformers would not
affect that separation, but do alter the possible hydrogen bonding interactions with the
imidazole ring, as hydrogen bond donor and acceptor groups on the ring have their relative
positions switched. One conformation about a single I45DC of the oligomer, relative to the
other I45DC conformer, may also be valuable as the oligomers optimize binding interactions
at protein interfaces. In this way the conformational isomers could be of added value in the use
of these oligomers in screening for inhibitors of protein-protein interactions.
Xu et al. Page 5
J Comb Chem. Author manuscript; available in PMC 2011 March 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Conclusion
A total of 317 final products in chemset 23 that were both analytically pure and of sufficient
quantity were submitted as HCl salts to the Molecular Library Small Molecule Repository
(MLSMR) for high-throughput screening by the as part of the NIH Roadmap. A total of 37
protected intermediates from chemset 22 where likewise submitted to the MLSMR. Chemical
and biological data for the oligomers will be accessible free of charge at PubChem
(http://pubchem.ncbi.nlm.nih.gov) as the compounds are incorporated into the database and
subsequently screened by the Molecular Libraries Probes Production Centers Network
(MLPCN). It is reasonably hypothesized that these oligomers will be valuable in the discovery
of inhibitors against protein-protein interactions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Scheme 2.
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Scheme 3.
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Scheme 4.
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Figure 1.
Comparison of the LC-MS trace (boxed) and aliphatic region in the 1H NMR spectra of 22
{2,1,2,2} (left) with 22{2,1,3,2} (right).
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Figure 2.
A partial 1H NMR spectrum of 22{2,1,3,2} recorded at 3 mM in DMSO-d6 at 30 °C. The
imidazole NHs, amide NHs (intramolecular hydrogen bonded as well as free amide) and
carbamate NH are labeled and indicate the presence of conformational isomers. Also shown
in the 2-CH of the imidazole (e) at 7.8 ppm. Two intramolecularly hydrogen bonded
conformations of 22{2,1,3,2} that differ about the I45DC acquired from chemset 21 are also
shown (A and B). The arrows underneath each imidazole indicate the direction of the
intramolecular hydrogen bond from donor to acceptor for that ring. The top conformer has the
same direction for each hydrogen bond and the bottom conformer has opposing directions.
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Table 1
N-Boc and Cbz protected amino acids, 1{2-3} and 7{2-3}, respectively, used in library synthesis.
Cmpd R1 Cmpd R2
1{2} CH3 7{2} CH3
1{3} CH2CH(CH3)2 7{3} CH2CH(CH3)2
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Table 2
Protected amino acids, 14{1-7} and 18{1-7}, respectively, used in library synthesis.
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